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Detection of ras Gene Mutations in Human
Lung Cancer: Comparison of Two Screening
Assays Based on the Polymerase Chain
Reaction
by Kirsti Husgafvel-Pursiainen,1 Maaret Ridanpaa,
Peter Hackman,' Sisko Anttila,1 Antti Karjalainen,
Agneta Onfelt,2 Anne-Lise B0rresen,3 and Harri
Vainio014
Westudiedtheprevalence ofpointmutations inras oncogenes(K-ras andN-ras) inDNAfromwhitebloodcells
and tumortissue from 36 untreated patients with non-small-cell lungcancer, all ofwhom were smokers or ex-
smokers. We observed somatic K-ras mutations in one-third of the lung carcinomas studied but no N-ras
mutation. K-ras codon 12 mutations were found more frequently in adenocarcinomas than in the other
histopathological subtypes studied. More than 60% (10/16) of the lung adenocarcinomas had a codon 12
mutation, most of which were G to T transversions. No mutation was found in white blood cell DNA. Two
polymerase chain reaction screening methods, oligonucleotide hybridization and denaturing gradient gel
electrophoresis (DGGE), were used to detect the mutations. The oligonucleotide method appears to be more
sensitive than DGGE, but DGGE proved to be a reliable nonradioactive method for rapid screening ofpoint
mutations in genes relevant to carcinogenesis.
Introduction
Various genetic alterations arekeyevents inthe process
leadingto the development ofcancer, both in experimental
animals and in humans. Among the alterations most fre-
quently associated with human malignancies are point
mutations in the ras oncogenes, H-ras, K-ras, and N-ras
(1,2), and in the proposed tumor-suppressor gene p53 (3-
5), all of which are involved in the regulation of cell
proliferation and differentation (6). Involvement of muta-
tionallyactivated ras geneshasbeenclearlydemonstrated
in several human cancers, includingthose ofthe pancreas,
colorectum, and lung, as well as in animal tumors induced
experimentally by exposure to carcinogens (1,7). Data
accumulated during the last few years strongly suggest
thatthese mutations in human tumors mayoriginate from
exposure to exogenous chemicals.
'Institute of Occupational Health, Helsinki, Finland.
2National Institute of Occupational Health, Solna, Sweden.
3The Norwegian Radium Hospital, Oslo, Norway.
4International Agency for Research on Cancer, Lyon, France.
Address reprint requests to K. Husgafvel-Pursiainen, Institute of
Occupational Health, Topeliuksenkatu 41 a A, SF-00250 Helsinki, Fin-
land.
We have investigated the prevalence ofpoint mutations
inK-rasandN-rasgenesofasetoflungcancerpatientsas
part of a larger study to elucidate the role ofexposure to
asbestos and smoking in the etiology of lung cancer in
Finland. The report by Anttila and her coworkers in this
issue describes other results from the same collaborative
effort (8).
We also sought a method that was simple and rapid
enough to allow screening for point mutations in genes
relevant to carcinogenesis in a large number of samples.
The objective was to adopt and further develop a method
suitablefordetectingpointmutationsinoncogenes,tumor-
suppressor genes, or genes involved in the metabolism of
xenobiotics, as anewtechniqueforbiomonitoring.Weused
the well-established method of dot blotting and oligo-
nucleotide hybridization (9) and comparedtheresultswith
those obtained using denaturing gradient gel elec-
trophoresis (DGGE) (10,11). Both methods are based on
amplification of DNA by the polymerase chain reaction
(PCR) in vitro (12).
Materials and Methods
DNAwas isolated and extracted fromwhite blood cells
and lung tumor tissue from 36 lung cancer patients (34HUSGAFVEL-PURSIAINEN ET AL.
male and 2 female patients, 35-79 years of age) by stan-
dardprocedures. PCRamplification ofthesequences stud-
ied in the oligohybridization assay (K-ras codons 12, 13,
and 61; N-ras codons 12 and 61) was performed as
described bySaiki et al. (13): 10-100 ngofgenomic DNAin
a total volume of 100 FL were amplified using 0.5 U of
AmpliTaq polymerase (Cetus) and a DNA thermal cycler
(Perkin-Elmer-Cetus), accordingtotheproceduresrecom-
mended by the manufacturers. The amplified DNA was
spotted on nylon membranes and probed by 32P-end-
labeled, mutation-specific oligonucleotides (Clontech Lab-
oratories). Each setof20-meroligonucleotides coveredthe
known activating point mutations ofa particulLr codon.
DGGE was performed as described earlier (14,15) and
an artificial GC-rich sequence was added onto one end of
the amplified fragments using GC-clamped primers (11).
The total length ofthe PCR products analyzed in DGGE
varied from 150 to 175 bp.
Results
The distribution of the histopathological types of lung
cancerinvestigatedandthemutationsfoundarepresented
in Table 1. All ofthe mutations detected in the 36 resected
lung tumors by either method were K-ras mutations: no
N-ras mutation was observed. The highest frequency of
K-ras mutations was found in adenocarcinomas, (>60%;
Table 1). The mostprevalent type ofmutationwas a Gto T
mutation in codon 12 or 13 ofK-ras; 6/16 adenocarcinomas
(37.5%) carried this mutation. Mutations of other types
were rare. All of these patients smoked for 21-46 years;
two had, however, stopped smoking several years pre-
viously. Neither K-ras nor N-rasmutationswere observed
in white blood cell DNA. The results are reported in more
detail elsewhere (K. Husgafvel-Pursiainen et al., in prepa-
ration).
Twelve mutations were detected by oligoprobing (Tlable
1), and nine ofthese were picked up by DGGE, with good
separation (Fig. 1). An additional mutation was found by
DGGE which remained undetected by oligohybridization.
The nature ofthis mutation is as yetunknown, butwe are
working on its sequencing.
Discussion
We report here the detection ofpoint mutations at the
K-ras oncogene in more than 60% of human lung ade-
nocarcinomas studied; similar results have been reported
byothers (16-19).ThepresenceofK-rasmutationsinthese
Table 1. Histological types oflung tumors studied and detection of
K-ras mutations by two methods.
No. of K-ras mutations
Histological type tumors Oligoprobe assay DGGE assay
Squamous-cell carcinoma 17 2 (12%) 2 (12%)
Adenocarcinoma 16 10 (63%) 7 (44%)
Small-cell carcinoma 3 0 0
Total 36 12 (33%) 9 (25%)
DGGE, denaturing gradient gel electrophoresis.
A
B
FIGURE 1. Detection ofpoint mutations in K-ras codon 61. (A) Adot-blot
of amplified DNA from tumors and white blood cells from lung cancer
patients; the DNAwas hybridized to a probe specific for a CAA to CAC
mutation resulting in histidine substitution. The double dot shows a
positive tumorsample, andthenexttwodots ontherightrepresentwhite
blood cell DNAfrom the same patient. (B) The same mutations detected
afterdenaturinggradientgelelectrophoresis andstainingwith ethidium
bromide. The lane with four bands shows separation of the mutated
molecules from wild-type ones. The corresponding white blood cell
sample is on the left.
tumors has been shown to be a strongindication ofa poor
prognosis (20), and a G to T transversion is not only the
most frequently observed type ofmutation, but has been
linked to smoking (18,21). We could not, however, demon-
strate a correlation between the amount of smoking-
related DNA adducts in peripheral lung tissue and the
mutations observed in the tumor tissue of individual
patients in preliminary 32P-postlabeling studies, even
though the adduct levels in peripheral lung tissue were
higher among smokers than amongpeople who had given
up smoking for several years (22). We have also observed
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high levels ofcytochrome P450IA in the lungs ofpatients
with peripheral adenocarcinomas who smoked (23).
The oligonucleotide hybridization assay appears, on the
basis of our results for the set of samples studied, to be
somewhat more sensitive than DGGE for detecting K-ras
mutations.WeexaminedfurthertheapplicabilityofDGGE
tothedetection ofrasgenemutationsbyconstructingand
running a set ofplasmid DNAs carrying N-ras mutations
as apositivecontrol. Excellentseparationwasachieved (K.
Burvall etal., inpreparation), sothatDGGE appearstobe
very suitable for preliminary screening oflarge numbers
of samples for point mutations: It is fast and requires no
probing or handling ofradioactive isotopes. DGGE and a
modification involving a constant gradient (15), do not
provide absolute identification ofthe mutations but, com-
bined with either oligoprobing, as described here, or
sequencing, it meets the primary screening criteria very
well, asreported recentlyforp53, anotherimportant gene
incarcinogenesis (24).
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